The objective of this order is to provide the cdrh and OCD with the professional support services of a SME IX to provide support related to the mdufa. The SME IX shall support the existing mdufa IV…
Ended Awarded Last action
- Contract number
- 75F40122F19213
- Awardee
-
Brillient Corporation UEI MMAVC7UGLJ78
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $1,016,930
Award facts
- Contract value 100% obligated
- $1,016,930.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- PSC
- R499 Support- Professional: Other
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Multiple Award, Fair Opportunity
- Pricing
- Labor Hours
- Place of performance
- Silver Spring, MD 20993, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $254,233 | |
| Exercise an Option | $254,233 | |
| Original award | $508,465 |
About this award
The Department of Health and Human Services Food and Drug Administration (HHS FDA) awarded a $1,016,930.08 Blanket Purchase Agreement (BPA) Call contract to Brillient Corporation, doing business as Brillient Corp, to provide Professional Support Services of a Subject Matter Expert IX (SME IX) in support of the Medical Device User Fee Amendments (MDUFA). The SME IX will support both the existing MDUFA IV and the reauthorization of MDUFA V. The contract is a Labor Hours pricing type contract to be performed in Silver Spring, Maryland over a two year period from April 2022 through May 2024. No subcontractors were identified.
Description
The objective of this order is to provide the cdrh and OCD with the professional support services of a SME IX to provide support related to the mdufa. The SME IX shall support the existing mdufa IV and the reauthorization of mdufa v.
Quick answers
Who was awarded contract 75F40122F19213?
75F40122F19213 was awarded to Brillient Corporation by Food and Drug Administration (Department of Health and Human Services) on April 22, 2022.
How much is contract 75F40122F19213 worth?
The government has obligated $1,016,930 on 75F40122F19213.
Is contract 75F40122F19213 an order under another contract?
Yes. 75F40122F19213 is a BPA call under GS00F012BA-HHSF223201810005B, a blanket purchase agreement, on Multiple Award Schedule (MAS).
Was contract 75F40122F19213 competed?
The extent of competition for 75F40122F19213 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award